Amarin Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
Amarin s intäkter har minskat med en genomsnittlig årlig takt på -19.3%, medan Biotechs -branschen såg intäkter på växande 33.8% årligen. Intäkterna har varit fallande med en genomsnittlig takt på 24.9% per år.
Viktig information
-19.32%
Tillväxttakt i vinsten
-18.59%
Tillväxttakt för EPS
| Biotechs Tillväxt i branschen | 17.04% |
| Intäkternas tillväxttakt | -24.94% |
| Avkastning på eget kapital | -7.48% |
| Nettomarginal | -15.51% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Apr 24
AMRN: Guideline Endorsements And Execution Risks Will Limit Future Share Returns
Analysts have maintained their fair value estimate for Amarin at $12.00. They made only minor adjustments to assumptions such as the discount rate and future P/E, which resulted in no change to the updated price target.Uppdatering av berättelse • Apr 08
AMRN: Guideline Support And Flat Earnings Outlook Will Restrain Future Upside
Narrative Update on Amarin Amarin's updated analyst price target holds steady at $12.00, as analysts point to only very small adjustments in discount rate, revenue growth assumptions, profit margin and future P/E that do not materially change their overall valuation view. Analyst Commentary Analysts covering Amarin are generally treating the current valuation as balanced, with the updated US$12.00 price target reflecting only modest tweaks to their core assumptions rather than a major shift in outlook.Uppdatering av berättelse • Mar 25
AMRN: Guideline Tailwinds And Earnings Assumptions Will Limit Future Upside Potential
Amarin's updated analyst price target holds steady at $12.00, with analysts pointing to only marginal tweaks in the discount rate and long-term P/E assumptions as they refine their valuation framework rather than rethink the story. Analyst Commentary Analysts covering Amarin are keeping the updated US$12.00 target steady, framing recent tweaks as fine tuning of their models rather than a shift in the fundamental view on the company.Uppdatering av berättelse • Mar 11
AMRN: Index Removal And Weaker Margins Will Restrict Future Upside Potential
Analysts have revised their price target on Amarin to $12.00, reflecting updated assumptions for revenue trends, profit margins, the discount rate, and a higher future P/E multiple in their models. Analyst Commentary Analysts revising their models for Amarin are focusing on how updated revenue and margin assumptions, along with the use of a higher P/E multiple, translate into the new US$12.00 price target.Uppdatering av berättelse • Feb 25
AMRN: Index Removal And Execution Risks Will Limit Future Upside Potential
Analysts have modestly adjusted their price target on Amarin, keeping fair value around $12.00. Small tweaks to the discount rate and future P/E assumptions refine their view rather than signal a major shift in the story.Uppdatering av berättelse • Feb 11
AMRN: Index Removal And Execution Risks Will Continue To Limit Upside
Analysts have adjusted their price target for Amarin to US$12.00. They attribute this move to slightly higher assumed discount rates, a modest tweak to long term revenue and margin expectations, and a small uplift in future P/E assumptions.Uppdatering av berättelse • Jan 27
AMRN: Index Removal And Execution Risks Will Constrain Future Upside Potential
Analysts have reaffirmed Amarin's fair value at US$12.00 per share, citing only modest tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the stock. Analyst Commentary Analysts are largely using the reaffirmed US$12.00 fair value as a reference point to stress test their assumptions on growth, profitability and execution risk for Amarin, rather than to rethink the overall thesis.Uppdatering av berättelse • Jan 12
AMRN: Index Removal And Weakening Revenue Outlook Will Constrain Future Upside Potential
Analysts have kept their fair value estimate for Amarin steady at US$12.00 per share, with only minor model tweaks to the discount rate, revenue trajectory and expected P/E that help to fine tune rather than shift their overall price target view. What's in the News Amarin issued revenue guidance for the fourth quarter of 2025, expecting net revenue of US$48 million to US$53 million, and for the full year 2025, expecting net revenue of US$212 million to US$217 million (corporate guidance).Analysartikel • Dec 10
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Uppdatering av berättelse • Dec 10
AMRN: Pricing And Competitive Pressures Will Likely Limit Future Upside Potential
Analysts have modestly lifted their price target on Amarin to $12.00 from $12.00. This reflects steady assumptions around long term discount rates, revenue growth, profit margins, and future earnings multiples despite a still cautious backdrop for the broader sector.Uppdatering av berättelse • Nov 26
AMRN: Rising Competitive Pressures Will Likely Challenge Future Profit Margin Expansion
Amarin's analyst price target has increased from $11.00 to $12.00. This reflects analysts' expectations of improved revenue growth and a notably stronger profit margin outlook for the company.Analysartikel • Oct 04
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a really impressive month, gaining 25% after a shaky period...Analysartikel • Jun 12
Amarin Corporation plc (NASDAQ:AMRN) Shares Fly 27% But Investors Aren't Buying For Growth
Amarin Corporation plc ( NASDAQ:AMRN ) shares have continued their recent momentum with a 27% gain in the last month...Analysartikel • Jun 12
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jun 06
Amarin Is A Sell Despite The Large Cash Balance
Summary Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with operating expenses exceeding product revenues, and European launches have not offset U.S. declines. Amarin trades below its cash value, providing some margin of safety and potential M&A appeal, but ongoing cash burn will erode this over time. Given the lack of clear catalysts and persistent losses, I expect Amarin to generate negative returns unless strategic action occurs soon. Read the full article on Seeking Alpha
Ny berättelse • Apr 01
I Foresee 49 Approvals Driving European And Global Market Expansion
Expanded regulatory approvals and commercialization in 49 markets support future revenue growth, particularly through focused expansion in Europe and worldwide.Analysartikel • Mar 15
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26%
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a horrible month, losing 26% after a relatively good period...Analysartikel • Jan 24
Amarin Corporation plc (NASDAQ:AMRN) Held Back By Insufficient Growth Even After Shares Climb 39%
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Analysartikel • Jan 03
Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysartikel • Oct 29
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1x Amarin Corporation plc ( NASDAQ:AMRN ) is definitely a...Analysartikel • Aug 01
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amarin fair value estimate is US$0.53 Amarin's US$0.68 share...Analysartikel • Jun 06
Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
The Amarin Corporation plc ( NASDAQ:AMRN ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Apr 16
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Summary Amarin is going through a turbulent period with a strong contraction in revenue and margins. The EU and China markets seem too small to make significant changes, and the US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin is reducing. My share price evaluation does not seem to offer positive returns on investment. Read the full article on Seeking AlphaAnalysartikel • Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Amarin Corporation plc ( NASDAQ:AMRN ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Jan 15
Amarin: Sarissa Is Giving Me Hope Again
Summary Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future. Read the full article on Seeking AlphaAnalysartikel • Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Analysartikel • Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Current share...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Amarin tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 217 | -34 | 100 | 19 |
| 31 Dec 25 | 214 | -39 | 115 | 20 |
| 30 Sep 25 | 227 | -86 | 132 | 20 |
| 30 Jun 25 | 219 | -104 | 149 | 21 |
| 31 Mar 25 | 214 | -88 | 149 | 21 |
| 31 Dec 24 | 229 | -82 | 152 | 21 |
| 30 Sep 24 | 241 | -39 | 159 | 21 |
| 30 Jun 24 | 265 | -34 | 168 | 21 |
| 31 Mar 24 | 277 | -53 | 180 | 22 |
| 31 Dec 23 | 307 | -59 | 200 | 22 |
| 30 Sep 23 | 322 | -52 | 224 | 22 |
| 30 Jun 23 | 346 | -38 | 237 | 22 |
| 31 Mar 23 | 361 | -91 | 273 | 26 |
| 31 Dec 22 | 369 | -106 | 304 | 30 |
| 30 Sep 22 | 423 | -92 | 329 | 31 |
| 30 Jun 22 | 476 | -100 | 373 | 33 |
| 31 Mar 22 | 536 | -22 | 393 | 30 |
| 31 Dec 21 | 583 | 8 | 408 | 29 |
| 30 Sep 21 | 606 | -2 | 433 | 32 |
| 30 Jun 21 | 620 | 4 | 450 | 34 |
| 31 Mar 21 | 601 | 1 | 435 | 38 |
| 31 Dec 20 | 614 | -18 | 463 | 39 |
| 30 Sep 20 | 590 | -16 | 443 | 42 |
| 30 Jun 20 | 546 | -13 | 405 | 40 |
| 31 Mar 20 | 511 | -19 | 386 | 37 |
| 31 Dec 19 | 430 | -23 | 324 | 34 |
| 30 Sep 19 | 364 | -63 | 307 | 35 |
| 30 Jun 19 | 307 | -84 | 275 | 40 |
| 31 Mar 19 | 259 | -117 | 255 | 51 |
| 31 Dec 18 | 229 | -116 | 227 | 56 |
| 30 Sep 18 | 206 | -105 | 183 | 56 |
| 30 Jun 18 | 198 | -92 | 166 | 53 |
| 31 Mar 18 | 190 | -71 | 144 | 48 |
| 31 Dec 17 | 181 | -68 | 135 | 47 |
| 30 Sep 17 | 166 | -73 | 130 | 45 |
| 30 Jun 17 | 151 | -78 | 123 | 48 |
| 31 Mar 17 | 139 | -78 | 118 | 47 |
| 31 Dec 16 | 130 | -86 | 111 | 50 |
| 30 Sep 16 | 118 | -81 | 104 | 53 |
| 30 Jun 16 | 107 | -97 | 104 | 53 |
| 31 Mar 16 | 91 | -147 | 104 | 52 |
| 31 Dec 15 | 82 | -149 | 101 | 51 |
| 30 Sep 15 | 72 | -147 | 96 | 50 |
| 30 Jun 15 | 64 | -141 | 88 | 52 |
Kvalitetsintäkter: AMRN är för närvarande olönsam.
Växande vinstmarginal: AMRN är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: AMRN är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 19.3% per år.
Accelererande tillväxt: Det går inte att jämföra AMRN s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: AMRN är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Biotechs branschen ( 43% ).
Avkastning på eget kapital
Hög ROE: AMRN har en negativ avkastning på eget kapital ( -7.48% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 04:19 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Amarin Corporation plc bevakas av 19 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Andrew Fein | Chardan Capital Markets, LLC |
| John Boris | Citigroup Inc |